Abstract:Objective To analyze the efficacy and safety of different treatments in advanced lung adenocarcinoma patients with v-raf murine sarcoma viral oncogene homolog B1(BRAF) BRAF V600E mutation, human epidermal growth factor receptor 2 (HER2) mutation, rearranged during transfection (RET) fusion gene and EGFR exon 20 insertion (EGFR 20-ins)mutations in order to provide references for clinical guidance. Methods A retrospective cohort study was performed on 14 patients with BRAF V600E mutation, 22 patients with HER2 mutation, 20 patients with RET fusion gene and 15 patients with EGFR 20-ins mutation who were admitted to our hospital between October 2019 and December 2021. The patients from different mutation groups were divided into chemotherapy±bevacizumab subgroup, chemotherapy+immune checkpoint inhibitors(ICIs) subgroup, and selective targeted drug subgroup. The efficacy and adverse events were compared in each mutation group. Results In the first-line treatment of the patients with BRAF V600E mutation, the median progression-free survival (mPFS) was longer in the dabrafenib-trametinib subgroup than the chemotherapy±bevacizumab subgroup and chemotherapy+ICIs subgroup (15.8 vs 6.3 and 4.7 months, P=0.426 5), but there were significant differences. In the first-line treatment of HER2-positive patients, the mPFS in the chemotherapy+immune subgroup was statistically better than the chemotherapy±bevacizumab subgroup and the HER2 inhibitor subgroup (8.7 vs 5.2 and 2.9 months, P=0.013 5). In the first-line treatment of the patients with RET fusion gene, the mPFS in the RET inhibitor subgroup was longer than that of the chemotherapy±bevacizumab subgroup and that of the chemotherapy+ICIs subgroup, without statistical significances (17.5 vs 7.8 and 6.7 months, P=0.092 3). Conclusion Targeted therapeutic drugs may be more effective in advanced lung adenocarcinoma patients with BRAF V600E mutation and RET fusion gene than those at first-line, while chemotherapy combined with immunotherapy may be more effective in the patients with HER2-positive at first line.

Supplementary Table S1 from Artemin-Stimulated Progression of Human Non–Small Cell Lung Carcinoma is Mediated by BCL2

Artemin-stimulated Progression of Human Non-Small Cell Lung Carcinoma is Mediated by BCL2.

Supplementary Data from Artemin-Stimulated Progression of Human Non–Small Cell Lung Carcinoma is Mediated by BCL2

Expression of cancer-testis antigen in patients with non-small cell lung cancer and its clinical relevance

Supplementary Table 4 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Supplementary Tables 1-3 from Serglycin Is a Theranostic Target in Nasopharyngeal Carcinoma that Promotes Metastasis

Prognostic Biomarkers after Radiotherapy for Nonsmall Cell Lung Cancer Based on Bioinformatics Analysis

Supplementary Table 2 from Proteomic Profiling Identifies Dysregulated Pathways in Small Cell Lung Cancer and Novel Therapeutic Targets Including PARP1

Table S1, S2, S3 from JAK1/STAT3 Activation through a Proinflammatory Cytokine Pathway Leads to Resistance to Molecularly Targeted Therapy in Non–Small Cell Lung Cancer

Gene Status and Clinicopathologic Characteristics of Lung Adeno-Carcinomas with Mediastinal Lymph Node Metastasis

Clinical characteristics and survival analysis of rare mutations in locally advanced or metastatic lung adenocarcinoma

Supplementary Table 5 from an Integrated Genome-Wide Approach to Discover Tumor-Specific Antigens As Potential Immunologic and Clinical Targets in Cancer

Supplementary Table 1 from Homozygous Deletions and Chromosome Amplifications in Human Lung Carcinomas Revealed by Single Nucleotide Polymorphism Array Analysis

The Pitx Gene Family As Potential Biomarkers And Therapeutic Targets In Lung Adenocarcinoma

Supplementary Tables 1 - 3 from Pathway-Based Serum microRNA Profiling and Survival in Patients with Advanced Stage Non–Small Cell Lung Cancer

Supplementary Tables from MetaLnc9 Facilitates Lung Cancer Metastasis via a PGK1-Activated AKT/mTOR Pathway

Association of genetic and immuno-characteristics with clinical outcomes in patients with RET-rearranged non-small cell lung cancer: a retrospective multicenter study

Prognostic Significance of the Expression of GFRα1, GFRα3 and Syndecan-3, Proteins Binding ARTEMIN, in Mammary Carcinoma.

Prognostic Roles Of Ctla-4 And Pdcd1 Gene Expression In Non-Small Cell Lung Cancer

The clinical significance of RET gene fusion among Chinese patients with lung cancer

Correlation of Genes Associated with Drug Response to Prognosis of Large Cell Lung Carcinoma.